GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hansa Biopharma AB (OSTO:HNSA) » Definitions » Net Interest Income (for Banks)

Hansa Biopharma AB (OSTO:HNSA) Net Interest Income (for Banks)


View and export this data going back to 2007. Start your Free Trial

What is Hansa Biopharma AB Net Interest Income (for Banks)?

Net Interest Income only applies to banks.


Hansa Biopharma AB (OSTO:HNSA) Business Description

Industry
Traded in Other Exchanges
Address
Scheelevagen 22, Lund, SWE, 223 63
Hansa Biopharma AB is a biopharmaceutical company that develops immunomodulatory treatments for enabling transplantations and rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection, and cancer. The company's product candidate, imlifidase, is an antibody-cleaving enzyme being developed to enable kidney transplantation in sensitized patients and further developed for use in other organ and tissue transplantation as well as acute autoimmune indications. It operates in Sweden, other European countries, and the U.S. The group generates the majority of its revenue from product sales.